Skip to main content

Quoin Pharmaceuticals Ltd 8-K, filed Nov 6, 2026

Quoin Pharmaceuticals Ltd. (QNRX)

8-K 2026-11-06 For: 2026-11-05
View Original
Added on November 06, 2026

About this 8-K

Quoin Pharmaceuticals Ltd filed this 8-K on November 6, 2026, reporting on events of November 5, 2026.

Quoin Pharmaceuticals Ltd. reported statistically significant interim Phase 2/3 QRX003 results in Netherton Syndrome, including 66.7% achieving the primary endpoint, alongside a private placement for up to approximately $50.0 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits